Group 1 - Wu Yifang has been appointed as the Chairman of the Board of Directors at Genscript Biotech (云顶新耀) after becoming an Executive Operating Partner at Kangqiao Capital [1][3] - The board adjustments at Genscript Biotech aim to enhance corporate governance, optimize strategic layout, and improve overall strength [1][3] - Wu Yifang has over 30 years of experience in the pharmaceutical industry and previously served as Chairman and CEO of Fosun Pharma, leading its transformation into a global biopharmaceutical leader [3] Group 2 - Genscript Biotech is focusing on developing its mRNA business, with a fully integrated and localized AI+mRNA platform targeting oncology and autoimmune diseases [3][4] - The company is advancing its product pipeline, including the universal therapeutic vaccine EVM14 and personalized therapeutic vaccine EVM16, with the first patient dosing of EVM16 completed in March this year [3] - Genscript Biotech is implementing a "dual-driven" strategy of "licensing in + independent research and development," aiming for operational profitability by the second half of 2025 [4]